Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168792 · ClinicalTrials.gov registry record · Phase 4
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1,671
- Enrollment target
NCT00168792 is a Phase 4 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 1,671 participants.
The verdict
NCT00168792, a Phase 4 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1,671 participants
- Enrollment target
Study Summary
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.
Interventions
- DRUG Tenecteplase
- PROCEDURE PCI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,671 participants |
| Start Date | 2003-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168792
The ClinicalTrials.gov registry entry for NCT00168792 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1,671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenecteplase is the first listed.
NCT00168792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168792 about?
NCT00168792 is a clinical study titled "A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)". To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.
What is the current status of trial NCT00168792?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1,671 participants. The study started on 2003-11.
What interventions are being tested in trial NCT00168792?
The interventions under investigation include: Tenecteplase (DRUG), PCI (PROCEDURE).
Who is sponsoring clinical trial NCT00168792?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.